The susceptibility of anti‐tumor immunotherapy peptides to plasma protein degradation, their short half‐life, poor intracellular delivery across cell membranes, and the immunosuppressive tumor microenvironment remain major obstacles to their effective systemic administration and therapeutic efficacy.[15, 61] In this study, we integrated multiple regulatory strategies, including PD‐L1 inhibition, biomimetic‐targeted delivery, and photothermal‐responsive release, to offer novel approaches and overcome these challenges. The gene discussed is CD274; the disease is neoplasm.